BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

Having found “hotspot” binding pockets in more than 20,000 proteins, Frontier Medicines is targeting these sites with a diverse library of starting points for small molecules, targeted protein degraders and autophagy inducers. Founded in 2018...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5 million...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

Led by Rick Klausner and Gregory Verdine, LifeMine has found drug candidates with novel mechanisms using its data science platform for mining fungal genomes. The company now has an additional $50 million to move its first programs toward...
BioCentury | Dec 22, 2020
Deals

Flagship’s Valo seeks cancer-like approach to CV drug development with G3 partnership

Valo’s partnership with G3 sheds more light on the Flagship Pioneering-built company’s in silico target discovery strategy, which the companies think will also identify new subtypes of disease. Valo Health LLC, which emerged from stealth...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the past month that aims to tackle the emerging space. On Thursday, the firm launched Faze Medicines Inc. to develop therapeutics targeting the...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

FDA approves Y-mAbs’ Danyelza for neuroblastomaShares of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) were up 17% in after-hours trading Wednesday after FDA granted accelerated approval to Danyelza naxitamab-gqgk plus GM-CSF to treat relapsed or refractory high-risk neuroblastoma....
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
Items per page:
1 - 10 of 2794
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

Having found “hotspot” binding pockets in more than 20,000 proteins, Frontier Medicines is targeting these sites with a diverse library of starting points for small molecules, targeted protein degraders and autophagy inducers. Founded in 2018...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5 million...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

Led by Rick Klausner and Gregory Verdine, LifeMine has found drug candidates with novel mechanisms using its data science platform for mining fungal genomes. The company now has an additional $50 million to move its first programs toward...
BioCentury | Dec 22, 2020
Deals

Flagship’s Valo seeks cancer-like approach to CV drug development with G3 partnership

Valo’s partnership with G3 sheds more light on the Flagship Pioneering-built company’s in silico target discovery strategy, which the companies think will also identify new subtypes of disease. Valo Health LLC, which emerged from stealth...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the past month that aims to tackle the emerging space. On Thursday, the firm launched Faze Medicines Inc. to develop therapeutics targeting the...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

FDA approves Y-mAbs’ Danyelza for neuroblastomaShares of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) were up 17% in after-hours trading Wednesday after FDA granted accelerated approval to Danyelza naxitamab-gqgk plus GM-CSF to treat relapsed or refractory high-risk neuroblastoma....
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
Items per page:
1 - 10 of 2794